N-Acetyl Semax, NASA
Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
NA-Semax (N-Acetyl Semax) is a modified version of Semax, a Russian-developed neuropeptide. The modification is proposed to improve stability. No published clinical or preclinical studies exist specifically on NA-Semax — all claims are extrapolated from the parent compound Semax.
No published studies found on PubMed.
NA-Semax has no marketing authorisation in any jurisdiction. No published clinical or preclinical studies exist specifically on this compound. All claims about its activity are extrapolated from the parent compound Semax (#106).
The absence of any compound-specific data means that the effects of N-acetylation on pharmacology, safety, and efficacy are unknown. Products available through unregulated channels lack pharmaceutical quality assurance.
No studies specific to NA-Semax have been published. The proposed mechanism is derived entirely from research on the parent compound Semax, which suggests neurotrophic factor modulation including BDNF upregulation. Whether the N-acetyl modification alters the pharmacological profile is not established.
No studies of any kind have been published specifically on NA-Semax. The parent compound Semax has a larger evidence base than Selank, including clinical use in Russia since 1996 — but the Alzheimer's Drug Discovery Foundation assessed it and concluded that well-conducted published studies are lacking. No randomised, double-blind, placebo-controlled trials of either Semax or NA-Semax have been published in English-language journals. Products from unregulated channels lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Pinealon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. The evidence base consists of in vitro cell studies and animal experiments published primarily by the originating research group. As with other Khavinson bioregulator peptides, the proposed mechanisms and the underlying theoretical framework have not been evaluated through conventional Western regulatory processes. Products available through unregulated channels lack pharmaceutical quality assurance.
Selank is approved in Russia for anxiety-related conditions. It has not been approved by the FDA, EMA, or other major Western regulatory agencies. The key clinical study (62 patients) compared Selank to a benzodiazepine in generalised anxiety disorder and reported comparable effects. Published clinical studies are predominantly Russian and have not undergone Western regulatory review. The evidence base does not meet FDA or EMA approval standards. Its regulatory status is limited to Russia and certain former Soviet states.
Semax is approved in Russia for stroke recovery and cognitive conditions. It has not been approved by the FDA, EMA, or other major Western regulatory agencies, and the clinical evidence base has not undergone Western regulatory review. Published clinical studies are predominantly Russian. The largest published study (110 stroke patients) reported correlations between treatment and BDNF levels. The evidence does not meet the standards typically required for FDA or EMA approval. Its regulatory status is limited to Russia and certain former Soviet states.
